HKD 0.12
(-14.71%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 172.27 Million HKD | -22.59% |
2022 | 222.55 Million HKD | 5.39% |
2021 | 211.16 Million HKD | -18.71% |
2020 | 259.78 Million HKD | 44.94% |
2019 | 179.23 Million HKD | 147.82% |
2018 | 72.32 Million HKD | 10.47% |
2017 | 65.47 Million HKD | 12.33% |
2016 | 58.28 Million HKD | -18.33% |
2015 | 71.36 Million HKD | 0.0% |
2013 | 140.93 Million HKD | 171.46% |
2012 | 51.91 Million HKD | 61.2% |
2011 | 32.2 Million HKD | 31.78% |
2010 | 24.44 Million HKD | -72.93% |
2009 | 90.29 Million HKD | 1219.18% |
2008 | 6.84 Million HKD | -52.17% |
2007 | 14.31 Million HKD | -38.87% |
2006 | 23.41 Million HKD | 24.14% |
2005 | 18.85 Million HKD | 19.05% |
2004 | 15.83 Million HKD | 26.89% |
2003 | 12.48 Million HKD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 176.6 Million HKD | 2.52% |
2024 Q2 | 176.6 Million HKD | 0.0% |
2023 FY | 172.27 Million HKD | -22.59% |
2023 Q3 | - HKD | -100.0% |
2023 Q2 | 230.69 Million HKD | 0.0% |
2023 Q1 | - HKD | -100.0% |
2023 Q4 | 172.27 Million HKD | 0.0% |
2022 FY | 222.55 Million HKD | 5.39% |
2022 Q4 | 222.55 Million HKD | 0.0% |
2022 Q2 | 226.72 Million HKD | 0.0% |
2021 FY | 211.16 Million HKD | -18.71% |
2021 Q4 | 211.16 Million HKD | 0.0% |
2021 Q2 | 235.92 Million HKD | 0.0% |
2020 FY | 259.78 Million HKD | 44.94% |
2020 Q2 | 211.14 Million HKD | 0.0% |
2020 Q4 | 259.78 Million HKD | 0.0% |
2019 Q4 | 179.23 Million HKD | 0.0% |
2019 Q2 | 126.68 Million HKD | 0.0% |
2019 FY | 179.23 Million HKD | 147.82% |
2018 Q2 | 64.09 Million HKD | 0.0% |
2018 FY | 72.32 Million HKD | 10.47% |
2018 Q4 | 72.32 Million HKD | 0.0% |
2017 FY | 65.47 Million HKD | 12.33% |
2017 Q2 | 56.93 Million HKD | 0.0% |
2017 Q4 | 65.47 Million HKD | 0.0% |
2016 FY | 58.28 Million HKD | -18.33% |
2016 Q4 | 58.28 Million HKD | 0.0% |
2016 Q2 | 105.36 Million HKD | 0.0% |
2015 Q4 | 71.36 Million HKD | 0.0% |
2015 Q2 | 115.47 Million HKD | 0.0% |
2015 FY | 71.36 Million HKD | 0.0% |
2014 Q2 | 140.93 Million HKD | 0.0% |
2013 Q2 | 51.91 Million HKD | 0.0% |
2013 FY | 140.93 Million HKD | 171.46% |
2013 Q4 | 62.1 Million HKD | 0.0% |
2012 Q2 | 32.2 Million HKD | 0.0% |
2012 Q4 | 38.01 Million HKD | 0.0% |
2012 FY | 51.91 Million HKD | 61.2% |
2011 Q2 | 24.44 Million HKD | 0.0% |
2011 Q4 | 6.64 Million HKD | 0.0% |
2011 FY | 32.2 Million HKD | 31.78% |
2010 Q4 | 64.02 Million HKD | 0.0% |
2010 FY | 24.44 Million HKD | -72.93% |
2010 Q2 | 90.29 Million HKD | 0.0% |
2009 Q2 | 6.84 Million HKD | 0.0% |
2009 FY | 90.29 Million HKD | 1219.18% |
2009 Q4 | 10.41 Million HKD | 0.0% |
2008 FY | 6.84 Million HKD | -52.17% |
2007 FY | 14.31 Million HKD | -38.87% |
2006 FY | 23.41 Million HKD | 24.14% |
2005 FY | 18.85 Million HKD | 19.05% |
2004 FY | 15.83 Million HKD | 26.89% |
2003 FY | 12.48 Million HKD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Natural Beauty Bio-Technology Limited | 308.05 Million HKD | 44.078% |
Innovative Pharmaceutical Biotech Limited | 1.06 Billion HKD | 83.803% |
China Overseas Nuoxin International Holdings Limited | 109.1 Million HKD | -57.901% |
Prosperous Future Holdings Limited | 177.1 Million HKD | 2.731% |
Huasheng International Holding Limited | 675.58 Million HKD | 74.5% |
Fourace Industries Group Holdings Limited | 61.8 Million HKD | -178.735% |
Evergreen Products Group Limited | 786.46 Million HKD | 78.095% |
EC Healthcare | 2.97 Billion HKD | 94.2% |
Ming Fai International Holdings Limited | 772.01 Million HKD | 77.685% |
Blue Moon Group Holdings Limited | 1.61 Billion HKD | 89.352% |
Takbo Group Holdings Limited | 42.84 Million HKD | -302.044% |
Hyfusin Group Holdings Limited | 181.34 Million HKD | 5.005% |